"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893))" by P. G. Pappas

Article

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893))

Clinical Infectious Diseases (2008)

P. G. Pappas, University of Alabama at Birmingham
C. M F Rotstein, Hamilton Health Sciences
R. F. Betts, University of Rochester
M. Nucci, Federal University of Rio de Janeiro
D. Talwar
J. J. De Waele
J. A. Vazquez, Wayne State University
B. F. Dupont, Necker-Enfants Malades Hospital
D. L. Horn, Thomas Jefferson University Hospital
L. Ostrosky-Zeichner, University of Texas at Austin
A. C. Reboli, Cooper Hospital
B. Suh, Temple University
R. Digumarti, Nizam's Institute of Medical Sciences
C. Wu, Astellas Pharma
L. L. Kovanda, Astellas Pharma
L. J. Arnold
D. N. Buell, Astellas Pharma

Link

Disciplines

Publication Date

July 15, 2008

DOI

10.1086/590000

Citation Information

P. G. Pappas, C. M F Rotstein, R. F. Betts, M. Nucci, et al.. "Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893))" Clinical Infectious Diseases Vol. 47 Iss. 2 (2008)
Available at: http://works.bepress.com/annette-reboli/30/